Goldman Sachs stock ticks up after leadership shake-up — what Wall Street watches next
29 January 2026
2 mins read

Goldman Sachs stock ticks up after leadership shake-up — what Wall Street watches next

New York, Jan 28, 2026, 21:13 ET — Market closed.

  • Goldman Sachs shares closed up 0.8% at $936.81 on Wednesday. 1
  • The bank broadened its Management Committee, adding seven leaders from Asset & Wealth Management. 2
  • Big Tech results after the bell and the Fed’s on-hold stance set the tone heading into Thursday’s session. 3

The Goldman Sachs Group Inc’s shares rose 0.8% to $936.81 on Wednesday, with the bank’s stock holding near the top of its day’s range even as the broader market struggled for direction. The shares traded between $923.20 and $937.40.

The move comes days after Goldman expanded its Management Committee — the firm’s top leadership group — with seven partners drawn from Asset & Wealth Management, the fee-driven business that manages money for clients. Chief executive David Solomon said the push to grow that franchise remains “a core strategic objective for the firm.” 4

It matters because Wall Street has been trying to handicap how fast Goldman can tilt its earnings mix toward steadier management fees, and away from businesses that can swing with dealmaking and markets. Business Insider, citing the firm, said the new appointments lift the committee count to 46, with the picks spanning private credit and wealth management roles. 5

Macro is still doing the heavy lifting for sentiment in U.S. financials. The Federal Reserve on Wednesday held its benchmark rate in the 3.50%-3.75% range, and Powell told reporters the economy “has once again surprised us with its strength,” while cautioning that inflation risks “still exist.” 6

In the equity market, the rate decision landed with a thud. “Whether you were bullish or bearish going into the press conference you walked away feeling about the same,” said Michael James, an equity sales trader at Rosenblatt Securities, after the Fed offered little clarity on when borrowing costs might fall again. 7

Stocks briefly flirted with another milestone earlier in the day, with the S&P 500 pushing past 7,000 before fading. “You could definitely have a continuation on the rally in equities if the earnings season shows that AI expenditure is bringing in revenues,” said Jeff Leschen, managing director at Bramshill Investments. 8

Goldman’s gain contrasted with a more mixed tape among big banks and brokers. JPMorgan Chase edged up 0.1%, while Morgan Stanley slipped 0.2% and Citigroup fell 0.6%.

But the backdrop can still turn fast. In a market-reaction note, MAI Capital’s Chris Grisanti called the Fed’s message “decidedly on the hawkish side” and said he didn’t see a rate cut “any time soon,” a setup that could test risk appetite if growth data cools or inflation stays sticky. 9

The next hard catalyst for Thursday is U.S. trade data. The Bureau of Economic Analysis is scheduled to publish international trade in goods and services for November 2025 at 8:30 a.m. ET. 10

Beyond that, traders will circle the February 6 employment report for January payrolls and wages — the next major read on whether the Fed can cut this year without losing the inflation fight. 11

Stock Market Today

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

Pfizer stock price rises into weekend as FDA priority review, TrumpRx discounts grab focus

7 February 2026
New York, February 7, 2026, 05:48 EST — Market closed Pfizer Inc (PFE) shares ended Friday up 2.8% at $27.22, after trading between $26.52 and $27.37. About 50.7 million shares changed hands. 1 The stock’s late-week lift comes with a key regulatory clock running: the FDA granted priority review for Pfizer’s supplemental filing to broaden use of its hemophilia drug Hympavzi, with a target decision deadline in the second quarter. Priority review shortens the agency’s standard review timeline by four months. “There is a significant medical need for younger patients with hemophilia and for those who have developed inhibitors,” Pfizer’s
Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next
Previous Story

Abbott stock slides after CEO’s $2 million buy hits SEC filing — what investors watch next

Uber stock drops 1.8% — Waabi robotaxi deal and Dutch driver ruling set up earnings test
Next Story

Uber stock drops 1.8% — Waabi robotaxi deal and Dutch driver ruling set up earnings test

Go toTop